Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

By sjmartinez • October 30, 2023

Cheema HA, Shafiee A, Athar MMT, Rafiei MA, Mehmannavaz A, Jafarabady K, Shahid A, Ahmad A, Ijaz SH, Dani SS, Minhas AMK, Nashwan AJ, Fudim M, Fonarow GC. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2023 Oct 12;10:1273781. doi: 10.3389/fcvm.2023.1273781. PMID: 37900570; PMCID: PMC10602781.

Tags: Cardiology/Epi, dapagliflozin, empagliflozin, heart failure, HFPEF, Publications, SGLT2I

Related Posts

Outcomes of Early Sodium-Glucose Cotransporter Two Inhibitor Use in Takotsubo Syndrome: Insights From a Multicenter Real-World Cohort Study

Taha A, Mondal A, Sandhyavenu H, Atti L, Alhajji M, Thangjui S, Shaik BF, Thyagaturu H, Caccamo M, Fonarow GC, Balla S. Outcomes of Early[...]

Trends in Alcohol-Related Deaths in the United States Over 55 Years: 1968-2023

Zulfiqar M, Uddin MS, Abbas F, Sajjad A, Uddin A, Shah SAA, Fonarow GC, Waqas SA, Yokolo H, Qureshi S. Trends in Alcohol-Related Deaths in[...]

Delivering Quadruple Therapy for Heart Failure With Reduced Ejection Fraction in a Customizable Polypill: The COMBO-HF-X Pilot Randomized Trial

DeJong C, Durstenfeld MS, Davis JD, Wang CS, Riley ED, Huffman MD, Hickey MD, Shade SB, Chen JC, Kazi DS, Grochowski J, Steward WT, Zier[...]